Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 15/20 | 1.00 |
| ▸ | BRD1 | O95696 | 8/20 | 0.68 |
| ▸ | BRD4 | O60885 | 6/20 | 0.68 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.68 |
| ▸ | BRPF3 | Q9ULD4 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31743118 | 0.89 | BRPF1 (0.80) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560655 | 0.85 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560702 | 0.84 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL19435605 | 0.81 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560677 | 0.81 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560722 | 0.80 | BRPF1 (0.79) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560671 | 0.79 | BRPF1 (0.77) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560680 | 0.78 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL7482731 | 0.78 | BRPF1 (0.63) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17576240 | 0.77 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | claimed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRPF1 104/4885BRD1 4/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.